The Food and Drug Administration launched a new website Tuesday that is part of an initiative to increase patient and healthcare providers’ access to drug safety information after a drug is approved. By evaluating medical studies, clinical trials and adverse drug events reported during product development, the site, Postmarketing Drug Safety Evaluations, aims to “improve the transparency of information about drugs and provide patients and healthcare providers better access to information about drugs.” So far, 26 recently approved drugs have been evaluated on the new FDA site. According to an article published Tuesday in the Wall Street Journal, the FDA didn’t find any adverse events that hadn’t already been reported in those 26 drugs’ labels.
The new FDA site represents a federal initiative to provide streamlined access to drug safety information and enhance patient outcomes. Although this is a step forward in decreasing adverse drug events and empowering patients and healthcare providers with more detailed drug safety information, it isn’t enough.
What healthcare providers need is access to Lexi-Comp’s drug information databases and interaction screening tools. When integrated into an EMR or various other healthcare applications, Lexi-Data – Lexi-Comp’s comprehensive drug database – provides healthcare providers with the clinical decision support data they need to improve patient safety and decrease the occurrence of adverse drug events. With drug-drug, drug-allergy and duplicate therapy interaction screenings, Lexi-Data allows the end user to be better-equipped to make sound decisions and positively affect patient safety.
The new FDA site represents a federal initiative to provide streamlined access to drug safety information and enhance patient outcomes. Although this is a step forward in decreasing adverse drug events and empowering patients and healthcare providers with more detailed drug safety information, it isn’t enough.
What healthcare providers need is access to Lexi-Comp’s drug information databases and interaction screening tools. When integrated into an EMR or various other healthcare applications, Lexi-Data – Lexi-Comp’s comprehensive drug database – provides healthcare providers with the clinical decision support data they need to improve patient safety and decrease the occurrence of adverse drug events. With drug-drug, drug-allergy and duplicate therapy interaction screenings, Lexi-Data allows the end user to be better-equipped to make sound decisions and positively affect patient safety.
Powered by Compendium
Comments for The FDA Takes Step to Decrease Adverse Drug Events